EpiCept Corporation has reported that the National Cancer Institute (NCI) has initiated a Phase II trial of crolibulin (EPC2407) in patients with anaplastic thyroid cancer (ATC).

The trial is designed to evaluate the efficacy and safety of crolibulin in combination with cisplatin in patients with ATC, and will enroll up to 70 patients.

The Phase II trial comprises two stages, in which, the primary objective of the first stage will be to assess the safety and tolerability of cisplatin and crolibulin.

The study will evaluate the toxicities of crolibulin in combination with cisplatin, evaluate dose-limiting toxicities (DLTs) and determine the maximum tolerated dose (MTD) for the combination.

The primary objective of the second stage of the trial will be to compare the combination of crolibulin and cisplatin versus cisplatin alone in adult ATC patients by evaluating the duration of progression-free survival (PFS).

An important secondary objective will be to compare the response rates evaluated by RECIST (response evaluation criteria in solid tumours).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

Crolibulin is a vascular disruption and apoptosis inducing agent, which demonstrated potent anti-tumour activity in both preclinical and early clinical studies.